Phase 3 Clinical Trial for Sickle Cell Disease: Betty Pace, MD, received a $178K, 2-year award from Mast Therapeutics, Inc…

Phase 3 Clinical Trial for Sickle Cell Disease:  Betty Pace, MD, received a $178K, 2-year  award from Mast Therapeutics, Inc. for “MST-188-01: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double blind, Placebo-Controlled Multicenter Trial of MST-188.”

The EPIC study will test an experimental compound called MST-188, which is designed to restore microvascular function that is compromised in a number of diseases, including sickle cell disease (SCD).  Specifically, the EPIC study will evaluate whether MST-188 can reduce 1) the duration of vaso-occlusive crisis (VOC) in subjects with SCD, and 2) the frequency of re-hospitalization due to a recurrence of VOC.  EPIC will also investigate the development of acute chest syndrome during VOC in subjects who receive MST-188.  The study officially opened at GRU on November 1, 2013 and will enroll nearly 400 individuals aged 8-17 with sickle cell anemia from participating academic centers across the United States through December 2015.

Written by
Allison Brown
View all articles
Written by Allison Brown

About Jagwire

Jagwire is the official source for news and stories from Augusta University and AU Health. Daily updates highlight the many ways students, faculty, staff, researchers and clinicians "bring their A games" in classrooms and clinics on four campuses in Augusta and locations across the state of Georgia. Read on for stories of innovation in education and health care, opportunities at the center of Georgia’s new cybersecurity hub, and experiential learning that blends arts and application, humanities and the health sciences. Have a story to share with Jaguar Nation? Contact the Division of Communications & Marketing.